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In recent years an increase of functional CD4+CD25+ regulatory T cells (Treg cells) has been established for patients with solid
tumors, acute leukemias, and lymphomas. We have reported an expanded pool of CD4+CD25high Treg cells in patients with
chronic lymphatic leukemia (CLL), multiple myeloma (MM) as well as its premalignant precursor monoclonal gammopathy of
undetermined signiﬁcance (MGUS). In healthy individuals, low-level expression of CD127 on T cells in addition to the expression
of FOXP3 has been associated with Treg cells. Here, we demonstrate that the expanded FOXP3+ T-cell population in patients
with colorectal cancer, CLL, MGUS, MM, follicular lymphoma, and Hodgkin’s disease are exclusively CD127low Treg cells and
were strongly suppressive. A signiﬁcant portion of CD127lowFOXP3+ Treg cells expressed only low levels of CD25 suggesting
that the previously reported expansion of CD25+ Treg cells underestimates the true expansion. The assessment of CCR7 and
CD45RA expression on the expanded CD4+CD127lowFOXP3+ Treg cells revealed an increase of both na¨ ı v ea sw e l la sc e n t r a la n d
eﬀector memory Treg cells in peripheral blood. Our data strongly support superiority of combined CD127 and FOXP3 analysis in
comparison to CD25 and FOXP3 assessment for further quantiﬁcation of Treg cells in malignant diseases.
1.Introduction
CD4+CD25+ regulatory T cells (Treg cells) are expanded
in murine tumor models, and their deletion can lead to
complete tumor regression [1]. In humans, Treg cells are
mostly enriched in the CD4+CD25high T-cell population
[2]. We and others have reported increased frequencies of
CD4+CD25highFOXP3+ Treg cells in cancer patients [1, 3].
However, the expansion of Treg cells based on the assessment
of CD25 is likely to underestimate the true expansion since
FOXP3+ T cells are also present in the CD25−/low fraction [4,
5]. Furthermore, molecular and functional characterization
of this population is hampered by the inability to separate
CD25+ Treg cells from activated eﬀector T cells. Two recent
studies, however, have shown that reciprocal expression of
the IL7 receptor (CD127) on FOXP3+ Treg cells is most likely
a more speciﬁc way to quantify FOXP3+ Treg cells [5, 6].
This has been adopted lately for the quantiﬁcation of Treg
cells in solid tumors [7–10] and hematologic malignancies
[11–13], with one of the reports establishing CD127 as an
even superior marker for the identiﬁcation of Treg cells in
cancer patients [9]. However, no systematic analysis has been
undertaken to establish CD127 as a superior marker for
Treg-cell enumeration in cancer patients, and only one in-
itial report of malignant melanoma patients has addressed
reciprocal expression of CD127 and FOXP3 on Treg cells in
cancer patients independently of CD25 [9]. It is, therefore,
necessary to determine whether CD127 is also a better mark-
er for enumerating FOXP3+ Treg cells in cancer patients in
general by comparing Treg cells numbers in a larger number
of diﬀerent tumor subtypes. Besides the integration of
CD25low/− FOXP3-expressing Treg cells, analysis of CD1272 Clinical and Developmental Immunology
might, furthermore, clarify contradictory results concerning
frequencies as well as prognostic value of Treg cells in cancer
patients [14–16].
Similarly, there is still debate whether human CD4+
CD25highFOXP3+ Treg solely belong to the memory T-cell
compartment [17]. Valmori et al. were the ﬁrst to iden-
tify a Treg-cell population with a na¨ ıve phenotype (CCR7+
CD45RA+), which they termed natural na¨ ıve Treg cells [18].
As expected, the frequency of these na¨ ıve Treg cells was rela-
tively low in healthy individuals [19]. More recently, Seddiki
et al. have described the persistence of a population of na¨ ıve
CD45RA+ Treg cells in adult life [20], which was further
characterized by resistance to CD95L-induced cell death
[21]. Recent data further supports that a population of na¨ ıve
Treg cells exist in healthy individuals that exerts suppressive
function [22]. So far, our own observations suggested an
increased frequency of na¨ ıve CD4+CD25highFOXP3+ Treg
cells in MM and MGUS [23]. However, previous ﬁndings
were restricted to the CD4+CD25high subpopulation exclud-
ing a signiﬁcant fraction of Treg cells from analysis. With the
emergence of CD127 as a new marker separating Treg cells
from conventional T cells, the question whether the ex-
panded Treg cells in cancer patients are mainly antigen-
experienced memory cells or also na¨ ıve Treg cells needs
reevaluation.
Here, we present clear evidence that FOXP3+ Tc e l l s
derived from patients with CLL, MGUS, MM, follicular
lymphoma (FL), Hodgkin’s disease (HD), and colorectal
cancer (CRC) are lacking CD127. This newly deﬁned fully
functional CD4+CD127lowFOXP3+ Treg-cell population is
expanded in all tumor entities as well as the premalig-
nant MGUS supporting the hypothesis of increased Treg
cells as a rather early event during tumor development.
Moreover, we demonstrate a signiﬁcant increase of na¨ ıve
CD4+CD127lowFOXP3+ Treg cells in peripheral blood of
cancer patients while we could not detect an increase in
lymph node biopsies of lymphoma patients. Finally, these
data strongly support the assessment of CD127 expression—
instead of CD25—in combination with FOXP3 for a more
precise enumeration of Treg cells in malignant diseases while
functional characterization still relies on the combination of
CD127 and CD25.
2.MaterialandMethods
2.1. Patients and Clinical Parameters. Following approval by
the institutional review board of the University of Cologne,
peripheral blood from 10 healthy individuals, 7 MGUS, 10
MM, 10 CLL and 6 patients with CRC (2 time points at least
1 month apart) was obtained after informed consent. For
the assessment of Treg cell numbers in lymph node biopsies,
lymph nodes from 7 healthy donors, 6 patients with HD,
and 7 patients with FL were analyzed following approval by
the institutional review board of the University of Cologne.
Patients were either untreated or had not received cytore-
ductive treatment for a period of at least 1 month prior
to investigation. Characteristics of the patients studied are
summarized in Tables 1 and 2.
2.2. Antibodies and FACS Analysis. Phenotype of T cells was
deﬁned by ﬂow cytometry using the following antibodies:
CD45RA-PE-Cy5 (HI100), CD127-PE (hIL-7R-M21), CD4-
APC-Cy7 (RPA-T4), CD25-PE-Cy7 (M-A251, all from Bec-
ton Dickinson), CCR7-FITC (150503, R&D) as well as the
correspondingisotypecontrolantibodies.Intracellularstain-
ing for FOXP3 was performed with FOXP3-APC (PCH101,
eBioscience) according to the manufacturer’s recommenda-
tions [23]. Samples were acquired on a FACS LSR II and
analyzed with FlowJo software (TreeStar Inc). Frequencies of
CD4+CD127lowFOXP3+ T cells are shown as percent values
of CD4+ T cells.
2.3. Isolation of CD4+CD127lowCD25+/low and CD4+CD127+
CD25− T Cells and Assessment of Inhibitory Function. To as-
sess the suppressive activity of CD4+CD127lowCD25+/low T
cells,amodiﬁedMLRwasperformedaspreviouslydescribed
[23]. Brieﬂy, CD4+CD127lowCD25+/low and CD4+CD127+
CD25− T cells were stained with CD4, CD25, and CD127
mAb and sorted on a FACSDiVa or FACS Aria III (both BD
Biosciences) and incubated for 20 hours with 10U/mL IL-2
(Proleukin) and 0.5μg/mL anti-CD3 (OKT3) in X-VIVO 15
(BioWhittakker) [24]. Subsequently, CD4+CD127+CD25−
T cells were stained with 5,6-Carboxyﬂuorescin-Diacetat-
Succinimidyl-Ester (CFSE, Sigma-Aldrich) and stimulated
in X-VIVO 15 supplemented with 10% fetal calf serum,
100U/mL penicillin/streptomycin and 2mM glutamine
(Invitrogen) with magnetic beads (Dynal Biotech,) coated
with 5% anti-CD3, 14% anti-CD28 (9.3), and 81% anti-
MHC class I (W6/32) at a ratio of 3:1 (cells:beads). To
assess inhibitory capacity of Treg cells from cancer patients,
autologous CD4+CD127lowCD25+/low Treg c e l l sw e r ea d d e d
at a 1:1 ratio to the culture, and the proliferation of
CD4+CD127+CD25− T cells was determined by assessing
CFSE dilution after four days of culture as described pre-
viously [23].
2.4. RNA Preparation and Quantitative Real-Time PCR. For
analysis of CD127 mRNA expression, CD4+CD25− and
CD4+CD25high T cells from ﬁve healthy donors and ﬁve
CLL patients were puriﬁed as previously described [24].
The described technique is optimized for the isolation of
human CD4+CD25high Tcellswithhighpurity[23,24].Cells
were reanalyzed after sorting and routinely showed >95%
purity. Subsequently, the cells were lysed in TRIzol reagent
(Invitrogen). 50–100ng RNA were reverse transcribed using
the Transcriptor First Strand cDNA Synthesis Kit (Roche,
Penzberg, Germany). Rt-PCR was performed with the
LightCyclerTaqman master kit and Universal ProbeLibrary
Assay on a Light Cycler 480 II. Analysis was performed
usingLight-Cycler3andRelQuantsoftwareusingacalibrator
normalized relative quantiﬁcation based on β-2 microglob-
ulin (B2M) expression. Primers used: CD127 forward, 5 -
AAAGTTTTAATGCACGATGTAGCTT-3 ; CD127 reverse,
5 - TGTGCTGGATAAATTCACATGC-3 ; Probe 72; B2M
forward, 5 - TTCTGGCCTGGAGGCTAT-3 ;B 2 Mr e v e r s e ,
5  TCAGGAAATTTGACTTTCCATTC-3 ; Probe 42.Clinical and Developmental Immunology 3
Table 1: Patient characteristics for Treg-cell assessment in peripheral blood.
(a) MGUS (peripheral blood)
ID Gender Age (yr) Stage Therapy Paraprotein Treg (%)
1M 3 7M G U S n o t x I g G / λ 3.6
2F 8 4M G U S n o t x I g A / κ 7.0
3F 8 6M G U S n o t x I g G / κ 7.5
4F 6 2M G U S n o t x I g A 6 . 0
5 M 52 MGUS no tx n.a. 6.8
6 F 79 MGUS no tx n.a. 2.4
7 M 65 MGUS no tx IgM/κ 8.0
(b) Multiple myeloma (peripheral blood)
ID Gender Age (yr) Stage Therapy Paraprotein Treg (%)
8M 6 2M M I A M I g G / κ 16.5
9 F 39 MM I A VAD, CAD, M, BMT IgG/κ 7.4
10 M 59 MM II A no tx IgG/κ 10.2
11 F 74 MM I A no tx IgG/λ 4.5
12 M 86 MM I A no tx IgG/κ 6.7
13 M 60 MM II A VAD, CAD, M, BMT IgG/κ 16.9
14 F 52 MM II A VID, C IgG/κ 4.4
15 M 59 MM II A TAD, CAD, M, BMT IgG/κ 8.6
16 F 67 MM II A VAD, CAD, M, BMT IgG/κ 22.2
17 M 53 MM II A no tx IgG/λ 8.0
(c) Chronic lymphocytic leukemia (peripheral blood)
ID Gender Age (yr) Stage Therapy Treg (%)
18 m 72 CLL A no tx 6.1
19 m 62 CLL A no tx 5.7
20 f 73 CLL A no tx 5.6
21 m 60 CLL B no tx 9.8
22 f 55 CLL B no tx 10.6
23 m 73 CLL B no tx 16.4
24 m 64 CLL B no tx 7.4
25 m 39 CLL C no tx 15.3
26 m 60 CLL C no tx 6.2
27 m 54 CLL C no tx 6.4
(d) Colorectal cancer (peripheral blood)
ID Gender Age (yr) Stage Primary tumor Sites of metastases Treg (%)
28 f 43 D Rectum Liver, bone, pararectal, para-aortal lymph nodes 7.5/10.4
29 f 32 D Colon Liver, spleen, ovaries, pelvis, peritoneum 5.7/9.3
30 m 57 D Rectum Lung 5.7/9.9
31 m 66 D Colon Liver 5.0/6.2
32 m 75 D Colon Liver 9.0/4.8
33 f 44 D Colon Liver 9.9/3.3
(e) Healthy donors (peripheral blood)
ID Gender Age (yr) Treg (%)
34 m 66 5.4
35 m 67 6.6
36 m 55 3.9
37 m 50 6.5
38 m 47 4.5
39 m 46 3.54 Clinical and Developmental Immunology
(e) Continued.
ID Gender Age (yr) Treg (%)
40 m 46 4.8
41 m 62 4.1
42 m 45 2.6
43 f 44 4.0
Patient characteristics including gender, age at analysis, Durie and Salmon, Binet or Dukes stage, ﬁrst diagnosis, primary tumor, sites of metastases, therapy,
paraprotein,andfrequencyofTreg cells.(f:female,m:male;therapy:A:Doxorubicin,BMT:autologousbone-marrowtransplantation,C:Cyclophosphamide,
I: Idarubicin, M: Melphalan, V: Vincristine, D: Prednisone, T: Thalidomide, no tx: no therapy, n.a.: not accessible.)
Table 2: Patient characteristics for Treg-cell assessment in lymph node biopsies.
(a) Follicular lymphoma (lymph node)
ID Gender Age (yr) Stage Therapy Treg (%)
44 m 59 FL I no tx 23.9
45 m 46 FL I no tx 13.4
46 f 58 FL I no tx 26.8
47 m 73 FL II no tx 19.6
48 f 66 FL II no tx 20.0
49 m 59 FL II no tx 13.2
50 m 57 FL II no tx 22.5
51 m 65 FL II no tx 37.5
(b) Hodgkin’s disease (lymph node)
ID Gender Age (yr) Entity Therapy Treg (%)
52 f 53 HD (ns) no tx 37.8
53 m 44 HD (ns) no tx 16.8
54 m 51 HD (ns) no tx 43.9
55 m 19 HD (ns) no tx 18.5
56 m 34 HD (ns) no tx 16.9
57 f 25 HD (mc) no tx 12.4
(c) Healthy donors (reactive lymph nodes)
ID Gender Age (yr) Treg (%)
58 m 35 4.9
59 f 18 11.7
60 f 17 4.9
61 m 22 9.7
62 f 45 16.7
63 m 39 8.9
64 m 24 14.0
Patient characteristics including gender, age at analysis, ﬁrst diagnosis, therapy, and frequency of Treg cells. (f: female, m: male; no tx: no therapy; mc: mixed
cellularity; ns: nodular sclerosing).
2.5. Statistical Analysis. Comparison between paired or un-
pairedgroupswasperformedusingtheappropriateStudent’s
t-test.AP-value<0.05wasdeﬁnedasstatisticallysigniﬁcant.
Due to the explorative nature of this study, no multiplic-
ity adjustment procedures were performed. All statistical
analyses were performed using the SPSS statistical software
package (SPSS 19.0, SPSS Inc.).
3. Results
3.1. Downregulation of CD127 mRNA Expression in CD4+
CD25high Treg Cells from CLL Patients. As CD25 is not solely
expressed on Treg cells but also on activated conventional
CD4+ T cells, and the downregulation of CD127 expression
in CD4+CD25high FOXP3+ Treg cells from healthy donors
h a sb e e nr e p o r t e d[ 5, 6], we ﬁrst assessed if CD127
downregulation is also apparent in CD4+CD25high Treg
cells from cancer patients. We detected a signiﬁcant down-
regulation of CD127 mRNA expression in CD4+CD25high
T cells from healthy donors (n = 5) as well as CLL
patients (n = 5, P<0.05, Figure 1(a)) by quantitative
PCR indicating that CD127 expression might also be used
to speciﬁcally identify CD4+FOXP3+ Treg cells in cancer
patients.Clinical and Developmental Immunology 5
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Figure 1: CD127 mRNA expression in CD4+CD25high Treg cells and integration of CD127 in the analysis of human Treg cells. (a) Expression
of CD127 mRNA in CD4+CD25high Treg cells and conventional CD4+CD25− T cells in healthy donors (n = 5, control) and CLL patients
(n = 5, CLL) as determined by qPCR (∗, P<0.05, Student’s t-test). (b) Gating strategies for analysis of expression of CD127 in
CD4+CD25highFOXP3+ Treg cells or (c) CD25 expression in CD4+CD127lowFOXP3+ Treg cells.
3.2.CoassessmentofCD127andFOXP3fortheEnumerationof
Human Treg Cells. Next the expression of CD127 in relation
to FOXP3 and CD25 was evaluated by ﬂow cytometry
on CD4+ T cells. Gating on CD4 and CD25 with subse-
quent analysis of the CD4+CD25high Treg-cell population for
expression of FOXP3 and CD127 conﬁrmed the downreg-
ulation of CD127 in CD4+CD25highFOXP3+ Treg cells on
protein level in healthy individuals (Figure 1(b)). However,
assessing coexpression of CD127 and FOXP3 by CD4+ T
cells without gating beforehand on the CD4+CD25high T-cell
population clearly revealed a signiﬁcantly higher percentage
of cells expressing FOXP3 but lacking CD127 (Figure 1(c)).
Subsequent analysis of the CD127lowFOXP3+ Treg-cell pop-
ulation for expression of CD25 demonstrated that gating
on CD127 and FOXP3 identiﬁes not only CD4+CD25high
Treg cells but also Treg cells expressing only low levels of
CD25 (Figure 1(c)). The identiﬁcation of this subpopulation
of Treg cells is of speciﬁc interest as up to now only Treg
cells expressing high amounts of CD25 were accessible to
functional analysis.
3.3. Increase of CD4+CD127lowFOXP3+ Treg Cells in Cancer
Patients. InclusionoftheCD25low Treg-cellsubpopulationin
the enumeration of Treg cells by deﬁning human Treg cells as
CD4+CD127lowFOXP3+ demands the reassessment of Treg-
cell frequencies in cancer patients as the actual frequencies
were probably underestimated until now. Comparison of
healthy individuals with cancer patients revealed elevated
levels of CD4+CD127lowFOXP3+ Treg cells in cancer and
MGUS patients, as exempliﬁed for individual patients in
Figures 2(a) and 2(b).I nt o t a l ,f r e q u e n c i e so fT reg cells
derived from peripheral blood of 12 patients with CRC,
10 CLL patients, 7 MGUS, and 10 MM patients as well as
10 healthy individuals were evaluated. In addition, lymph
node biopsies from 7 patients with follicular lymphoma, 6
patients with Hodgkin’s disease, and 7 reactive lymph nodes
from healthy individuals were assessed for expanded Treg-
cell numbers. Gating on CD4 and CD25 with subsequent
gating on FOXP3 conﬁrmed the already described increase
of Treg cells in patients with CRC, CLL, MGUS, MM, FL,
and HD (Figures 3(a) and 3(b) and Tables 3 and 4). More
important, when gating on FOXP3 and CD127 without
using CD25 as primary inclusion criteria, frequencies of
CD4+CD127lowFOXP3+ Treg c e l l si nc o n t r o l s( 4 .1% ± 0.7%)
were similar to previously published results (Figure 3(c)
and Table 3)[ 2, 5, 6, 24]. In contrast, individuals with
CRC (7.2% ± 2.4%, P<0.005), CLL (8.9% ± 4.0%, P<
0.005), as well as MM (11.7% ± 5.4%, P<0.005) showed
signiﬁcantly increased frequencies of CD127lowFOXP3+ Treg
cells compared to healthy individuals (Figure 3(c) and
Table 3). Even in MGUS patients, a signiﬁcantly higher
frequency of Treg cells (6.0% ± 1.8%, P<0.05) was ob-
served (Figure 3(c) and Table 3), which is indicative of
Treg-cell expansion as an early event in tumorigenesis.
Similarly, we observed signiﬁcantly increased frequencies of
CD127lowFOXP3+ Treg cells in patients with FL (21.8% ±
8.0%, P<0.01) and HD (24.4% ± 13.1%, P<0.05) in
comparison to reactive lymph node specimens from healthy
individuals(10.1%±4.4,Figure 3(d)andTable 4).Moreover,
the percentage of FOXP3+ cells within the CD4+CD127low
T-cell population was always higher than within the
CD4+CD25high population, suggesting that previous data
only assessing a CD4+CD25high phenotype have underesti-
mated the absolute increase of FOXP3+ Treg cells in cancer
patients (Tables 3 and 4).6 Clinical and Developmental Immunology
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Figure 2: Frequency of CD4+CD127lowFOXP3+ Treg cells. Flow cytometric analysis of CD127 and FOXP3 expression in CD4+ Tc e l l sf r o m
(a) peripheral blood of a representative healthy individual (control) and representative patients with colorectal cancer (CRC), CLL, MGUS,
and multiple myeloma (MM) and (b) lymph node biopsies from a healthy individual (reactive) and patients with follicular lymphoma (FL)
and Hodgkin’s diseases (HD).
Table 3: Assessment of Treg-cell frequencies in peripheral blood.
Control Colon CLL MGUS MM
Mean (SD) Mean (SD) P Mean (SD) P Mean (SD) P Mean (SD) P
CD4+CD127low 4.6 (1.3) 7.6 (1.5) <0.001 8.3 (2.5) <0.005 5.4 (1.3) n.s. 11.2 (5.9) <0.01
CD4+CD127lowFOXP3+ 4.1 (0.7) 7.2 (2.4) <0.005 8.9 (4.0) <0.005 6.0 (1.8) <0.05 11.7 (5.4) <0.005
CD4+CD127lowFOXP3+CD25high 2.5 (0.6) 4.3 (1.6) <0.005 4.7 (2.7) <0.05 3.9 (1.3) <0.05 7.1 (4.9) <0.05
CD4+CD25high 2.8 (0.9) 7.6 (1.2) <0.001 6.4 (1.8) <0.001 4.5 (1.1) <0.05 9.0 (5.3) <0.01
CD4+CD25highCD127low 2.9 (0.9) 4.5 (1.2) <0.005 4.5 (2.0) <0.05 3.5 (1.3) n.s. 7.0 (5.1) <0.05
CD4+CD25highFOXP3+ 2.1 (0.8) 4.2 (1.2) <0.001 3.6 (1.7) <0.05 2.5 (0.6) n.s. 6.3 (4.5) <0.05
CD4+FOXP3+ 2.8 (0.9) 4.7 (2.1) <0.05 4.7 (2.4) <0.05 3.6 (1.1) n.s. 7.7 (5.1) <0.05
Deﬁnition of subpopulations based on expression of CD25, CD127, and FOXP3 (SD: standard deviation, n.s.: not signiﬁcant).
3.4. CD4+CD127lowCD25+/low Treg Cells are Fully Functional
in Cancer Patients. As intracellular FOXP3 staining is not
applicable for functional analysis of Treg cells, classiﬁcation
of FOXP3+ Treg cells based solely on cell surface markers
is necessary. The characterization of FOXP3+ Treg cells was
best achieved when combining CD127 and CD25 (Figures
4(a) and 4(b)). We, therefore, used this combination of
cell surface markers to sort Treg cells for functional anal-
ysis. Staining for FOXP3 expression after sorting routinely
showed purities of CD4+CD127lowFOXP3+CD25+/low Treg
cells >95 percent (Figure 4(b)). To determine whether
the CD4+CD127lowCD25+/low Treg cells from cancer pa-
tients are functional, we used an in vitro suppression
assay. When activated with CD3/CD28 beads conven-
tional CD4+CD127+CD25− T cells, but not CD4+CD127low
CD25+/low Treg cells, proliferate strongly. In the presence
of CD4+CD127lowCD25+/low Treg cells, this proliferation is
suppressed(Figure 4(c)).Thesedataclearlydemonstratethat
CD4+CD127lowCD25+/low T cells are FOXP3+ and that these
cells are fully functional in CRC patients.
3.5. Na¨ ıve CD4+CD127lowFOXP3+ Treg Cells are Increased in
Peripheral Blood of Cancer Patients. In healthy individuals,
Treg cells have been shown to exist at all diﬀerentiation
states, namely, na¨ ıve, central, and eﬀector memory Treg cells
[18, 20, 25]. To determine which Treg-cell subpopulation
is responsible for the increase of CD4+CD127lowFOXP3+
Treg cells in cancer patients, we determined the frequency
of na¨ ıve, central, and eﬀector memory cells within the
Treg-cell compartment from healthy individuals, CRC,
CLL, MGUS, and MM patients (Figure 5(a))a n dc o m -
pared these data with those previously described for
CD4+CD25high Treg cells in healthy individuals as well as
MGUS and MM patients [18, 23]. In healthy individu-
als, na¨ ıve CCR7+CD45RA+CD4+CD127lowFOXP3+ Treg cells
were hardly detectable (Figures 5(b) and 5(c)). Treg cells wereClinical and Developmental Immunology 7
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Figure 3: Assessment of Treg- c e l lf r e q u e n c i e s .F r e q u e n c yo fC D 4 +CD25highFOXP3+ Treg cells in (a) peripheral blood of 10 healthy donors
(control), 12 colorectal cancer (CRC), 10 CLL, 7 MGUS, and 10 multiple myeloma (MM) patients and (b) 7 reactive lymph node biopsies
from healthy individuals (reactive), 7 patients with follicular lymphoma (FL), and 6 patients with Hodgkin’s disease (HD). (c) and (d)
Frequencies of CD4+CD127lowFOXP3+ Treg cells in the respective groups. Error bars represent standard deviation (∗, P<0.05, Student’s t
test).
almost exclusively of memory phenotype (Figures 5(b) and
5(c)).In contrast,in peripheral blood of CRC, CLL, andMM
patients, a signiﬁcant expansion of CD4+CD127lowFOXP3+
Treg cells with a na¨ ıve phenotype was observed (Figures
5(b) and 5(c)). The expansion of na¨ ıve Treg cells was
apparent as part of the Treg-cell pool as well as in relation
to the total number of CD4+ T cells in cancer patients.
This increase in na¨ ıve Treg cells was further accompanied
by an expansion of Treg cells with a central as well as
eﬀector memory phenotype in all patient groups (Figures
5(b) and 5(c)). Interestingly, the observed expansion of
na¨ ıveCD4+CD127lowFOXP3+ Treg cellswasalsodetectablein
MGUS patients (Figures 5(b) and 5(c)) further underlining
that frequencies of na¨ ıve Treg cells increase rather early
during tumor development and progression. When assessing
subpopulations of Treg cells in lymph node specimens, we
observed a predominance of CD4+CD127lowFOXP3+ Treg
cells with a central-memory phenotype, with a signiﬁcantly8 Clinical and Developmental Immunology
Table 4: Assessment of Treg-cell frequencies in lymph node biopsies.
Control FL HD
Mean (SD) Mean (SD) P Mean (SD) P
CD4+CD127low 54.7 (23.1) 68.6 (15.8) >0.05 68.0 (12.7) >0.05
CD4+CD127lowFOXP3+ 10.1 (4.4) 21.8 (8.0) <0.01 24.4 (13.1) <0.05
CD4+CD127lowFOXP3+CD25high 3.1 (1.9) 11.7 (5.5) <0.005 6.4 (2.3) <0.05
CD4+CD25high 5.1 (2.9) 13.8 (7.1) <0.05 11.2 (3.3) <0.005
CD4+CD25highCD127low 4.1 (3.0) 16.3 (7.1) <0.005 11.3 (5.2) <0.05
CD4+CD25highFOXP3+ 2.9 (2.6) 10.0 (5.4) <0.01 5.6 (1.2) <0.05
CD4+FOXP3+ 10.3 (5.5) 19.4 (8.5) <0.05 23.4 (12.0) <0.05
Deﬁnition of subpopulations based on expression of CD25, CD127, and FOXP3 (SD: standard deviation, n.s.: not signiﬁcant).
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Figure 4: Functional analysis of CD4+CD127lowCD25+ Treg cells in cancer patients. (a) Sorting strategy for isolating CD4+CD127lowCD25+
Treg cells(Treg)aswellasconventionalCD4+CD127+CD25− Tcells(T conv).(b)ExpressionofFOXP3inthecorrespondingT-cellpopulations.
(c)PercentageofproliferationofCD4+CD25−CD127+ Tconv cells(blackbar)aloneorcultivatedwithCD4+CD127lowCD25+ Treg cells derived
from CRC patients (n = 4) at a 1:1 ratio (white bar) both in the presence of CD3/CD28 mAb coated beads. Error bars represent standard
deviation (∗, P<0.05, Student’s t test).
expanded population of central-memory Treg cells apparent
in patients with FL and HD (Figure 5(d)). In addition, we
could also detect an increase in eﬀector-memory Treg cells
(Figure 5(d)) while the pool of na¨ ıve Treg cells was basically
absent independent if reactive or diseased lymph nodes were
analyzed (Figure 5(d)).
4. Discussion
Expansion of CD4+CD25high Treg cells within the tumor
microenvironment and peripheral blood has so far been
accepted as a hallmark of cancer [1, 26, 27]. Moreover,
augmented Treg-cell frequencies have been linked to tumor
stage, prognosis, and survival [1, 26, 27]. We present new
evidence that the increase of Treg cells in cancer was even
underestimated previously due to suboptimal classiﬁcation
of Treg cells. Integrating analysis of FOXP3 with the cell-
surface molecule CD127 clearly demonstrates that signiﬁ-
cantly higher numbers of CD127lowFOXP3+ Treg cells are
expanded in cancer patients in general. The assessment of
CD127 instead of CD25 is clearly superior in enumerating
Treg cells in the diseased state.
Natural Treg cells have been described as CD4+CD25+ T
cells in mice [28], and initial reports in cancer patients relied
solely on the assessment of CD4 and CD25 expression for
the identiﬁcation of Treg cells [3, 29]. Only since the identi-
ﬁcation of the transcription factor FOXP3 lineage-speciﬁc
marker of Treg cells a more speciﬁc characterization of Treg
cells is possible [28]. In murine models, FOXP3 expression
is strongly associated with the CD25+ Treg-cell population.
However, even the inclusion of FOXP3 assessment has been
interpreted diﬀerentially when assessing frequencies of Treg
cells in healthy individuals and cancer patients [23, 30].
The analysis of Treg c e l l si nh u m a n sh a sb e e nf u r t h e r
complicated as several studies reported FOXP3+ cells within
the CD4+CD25low or even CD4+CD25− population [5],
and even the reprogramming of Treg cells into eﬀector T
cells has been reported [31]. Therefore, a more speciﬁc
deﬁnition of Treg cells based on unique or additional Treg-
cell marker molecules is urgently needed. The introduction
of CD127 as a new marker to distinguish Treg cells fromClinical and Developmental Immunology 9
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Figure 5: Assessment of na¨ ıve CCR7+CD45RA+CD4+CD127lowFOXP3+ Treg cells. (a) Frequencies of CCR7+CD45RA+ na¨ ıve
CD4+CD127lowFOXP3+ Treg cells (Tnaive), CCR7+CD45RA−CD4+CD127lowFOXP3+ central memory Treg cells (TCM), and
CCR7−CD45RA−CD4+CD127lowFOXP3+ eﬀector memory Treg cells (TEM) were assessed in peripheral blood using gating on CD127
and FOXP3 with successive gating on CCR7 and CD45RA. (b) Flow cytometric analysis of na¨ ıve, central memory, and eﬀector memory
CD4+CD127lowFOXP3+ Treg cells in peripheral blood from a representative healthy individual (control) as well as representative patients
with colorectal cancer (CRC), CLL, MGUS, and multiple myeloma (MM). Frequencies of regulatory Tnaive,T CM, and TEM cells were assessed
in (c) peripheral blood of CRC (CRC, n = 12), CLL (CLL, n = 10), MGUS (MGUS, n = 7), MM (MM, n = 10), and healthy individuals
(control, n = 10) and (d) 7 reactive lymph node biopsies from healthy individuals (reactive), 7 patients with follicular lymphoma (FL), and
6 patients with Hodgkin’s disease (HD). Error bars represent standard deviation (∗, P<0.05, Student’s t-test).
conventional T cells is an important improvement and will
help to clarify several previous conﬂicting results in human
Treg-cell biology, particularly in cancer patients.
Several recent studies have adopted the approach to use
CD127, CD25, and FOXP3 for the quantiﬁcation of Treg
cells in tumor-bearing individuals and could demonstrate
increased numbers of CD4+CD25highCD127low Treg cells
in patients with solid tumors [7–10] and hematologic
malignancies[11–13].However,themajorityofthesereports
focused solely on the enumeration of the Treg-cell compart-
mentwhileatthesametimefocusingononlyonetumorsub-
type.OnlyonestudyassessedTreg-cellnumbersinmorethan
one tumor subtype showing similar numbers of Treg cells
for all gastrointestinal tumor subtypes analyzed [8]. Further-
more, these studies did not systematically compare possible
markercombinationstoestablishthemostsuitableapproach
to identify Treg cells. This was analyzed in more detail in
only one of the reports with the combination of CD127 and10 Clinical and Developmental Immunology
FOXP3 being the most appropriate combination to identify
Treg cells in patients with malignant melanoma [9].
The integration of CD127 permits to redeﬁne the
importance of CD25 expression on human Treg cells. Up to
now, high expression of CD25 allowed for an enrichment
of CD4+ T cells with regulatory properties [2]. However, it
is undisputed that neither all human Treg cells are included
by this approach nor that activated T cells expressing CD25
are excluded. Zelenay et al. could demonstrate a population
of CD4+CD25−FOXP3+ T cells which can upregulate CD25
upon the depletion of all CD25 expressing cells and are able
to replace the original Treg-cell population [4]. These data
were a ﬁrst hint that the expression of CD25 on Treg cells
is similarly regulated like its expression on conventional T
cells [4]. Human Treg cells need IL-2 for their survival and
proliferation, and expression of the IL2R-α chain is certainly
a prerequisite for IL-2 to exert its biological function [32].
However, the expression of CD25 is not homogenous and
might also be dependent on the activation status and other
exogenous factors [33].
Using CD127 and FOXP3 to deﬁne human Treg
cells demonstrates varying expression of CD25 in the
CD4+CD127lowFOXP3+ Treg-cell population. Additionally,
the newly deﬁned Treg-cell population comprises of sig-
niﬁcantly more Treg cells compared to the traditionally
deﬁned CD4+CD25high Treg cells as demonstrated recently
for malignant melanoma [9]. Coassessment of CD127 and
FOXP3 to determine Treg cells also resolves the uncertainty
to diﬀerentiate between activated conventional T cells and
Treg cells in patients with active disease. This is of particular
importance when only using CD4 and CD25 for the iden-
tiﬁcation of Treg cells in cancer patients, as contamination
with eﬀector T cells most frequently occurs when solely these
two markers are used for analysis. As functional assessment
of the CD4+CD127lowFOXP3+ Treg-cell population is not
possible as FOXP3 cannot be used for live studies of human
Treg cells, using expression of CD4, CD25, and CD127 is the
bestpossibleapproximation.Tcellsisolatedbythisapproach
almost exclusively express FOXP3. Moreover, when isolated
from cancer patients, this Treg-cell population exerts strong
inhibition.
Using a comparative approach analyzing diﬀerent tumor
subtypes from hematologic as well as epithelial ori-
gin, we demonstrate that all independent cancer patient
groups studied uniformly show an expanded pool of
CD4+CD127lowFOXP3+ Treg cells.Wethereforepostulatethat
expansion of Treg cells is a general phenomenon in can-
cer patients. Moreover, since MGUS patients already have
increased frequencies of Treg cells, it is very likely that
expansion of Treg cells is an early event in the development of
human tumors. Elevated Treg-cell levels might be associated
with the progression from premalignant lesions that are still
under control of the immune system to the uninhibited
growth of malignant tumors.
Theﬁndingsthatna¨ ıveTreg cellsareincreasedbothinthe
premalignant state as well as in cancer patients might further
support this hypothesis. Treg cells were ﬁrst identiﬁed as
antigen-experienced memory cells expressing CD45RO [2].
Onlyrecentlytheexistenceofna¨ ıveTreg cellsinhumanadults
h a sb e e nr e p o r t e d[ 18, 20, 22, 23, 34], and the na¨ ıve Treg-cell
population can be expanded in vitro while retaining its sup-
pressive function [35, 36]. However, the physiological func-
tion of the na¨ ıve Treg-cell population remains unclear. Deﬁ-
nition of Treg cells as CD4+CD127lowFOXP3+ has enabled us
to verify the increase of na¨ ıve Treg cells in MGUS and MM
patients [23] and to extend these ﬁndings to CLL and CRC.
The identiﬁcation of an expanded pool of na¨ ıve Treg cells
in cancer patients opens new avenues to better understand
the role of Treg cells in malignant disease. Memory Treg cells
apparently cannot undergo self-renewal [37]. Therefore, the
replenishment of an increased memory Treg-cell pool by
diﬀerentiation of na¨ ıve Treg cells into memory Treg cells
might be an alternative to the recently proposed conversion
of conventional memory T cells to Treg cells [37]. In fact, the
increased pool of na¨ ıve Treg cells with an unaltered frequency
of memory Treg cells in premalignant MGUS suggests that
expansion of na¨ ıve Treg cells is indeed preceding the expan-
sion of memory Treg cells following diﬀerentiation during
tumor development. Besides the expansion of na¨ ıve Treg
cells through enhanced self-renewal and diﬀerentiation,
other mechanisms have been proposed amongst them the
interaction of CCR4 on Treg cells with CCL22 released in the
tumor microenvironment [38] as well as the conversion of
conventional CD4+CD25− T cells to Treg cells trough TGF-
β [39] or prostaglandin E2 [40]. How these factors inﬂuence
the expansion of na¨ ıve Treg cells needs further clariﬁcation
and might in the end result in better strategies to target
expanded Treg cells in tumor patients.
In conclusion this study demonstrates that CD4+
CD127lowFOXP3+ Treg cells are increased in cancer patients.
Deﬁnition of Treg cells by combining CD127 and FOXP3 has
the advantage of including not only Treg cells expressing high
levels of CD25 but also Treg cells with low CD25 expression
andexcludingatthesametimeactivatedconventionalTcells.
Furthermore,thena¨ ıveTreg-cellpopulationisexpandedinall
tumor bearing individuals.
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